1
|
Ling CG, Chen JF, Wang XC. Effect of gamma knife stereotactic radiotherapy on the hematological system in patients with advanced lung cancer and its therapeutic effect. Am J Cancer Res 2025; 15:1777-1789. [PMID: 40371142 PMCID: PMC12070111 DOI: 10.62347/kmwi9314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2024] [Accepted: 03/19/2025] [Indexed: 05/16/2025] Open
Abstract
OBJECTIVE To evaluate the influence of Gamma Knife stereotactic body radiotherapy (SBRT) on the hematological system in patients with advanced lung cancer and to assess its clinical outcomes. METHODS A retrospective analysis was conducted on the clinical data of 192 patients with advanced lung cancer. 108 patients who received conventional radiotherapy were included in the control group, and the rest 84 patients who received Gamma Knife SBRT were included in the experimental group. Treatment outcomes, disease progression one year after radiotherapy, blood cell counts, coagulation function, quality of survival scores, and adverse reactions were compared between the two groups. RESULTS The experimental group exhibited a significantly higher disease control rate (DCR) and objective response rate (ORR) compared to the control group (both P<0.05). Radiotherapy modality was identified as an independent factor influencing disease progression within one year. Both groups experienced reductions in leukocytes, neutrophils, lymphocytes, erythrocytes, and platelets after radiotherapy, but the experimental group had less pronounced reductions (P<0.05). Alterations in blood cell morphology were observed in both groups, with the experimental group showing fewer alterations (P<0.05). Coagulation function tests indicated a rise in prothrombin time (PT), a decrease in activated partial thromboplastin time (APTT), and an increase in fibrinogen (Fib) and D-Dimer (D-D) levels in both groups, with more favorable coagulation indices observed in the experimental group. Patients in both groups showed improvement in quality of survival scores post-treatment, with the experimental group outperforming the control group (P<0.05). The incidence of adverse reactions was lower in the experimental group compared to the control group (P<0.05). CONCLUSION Compared to traditional radiotherapy, Gamma Knife SBRT has a less detrimental impact on the blood cell level, morphology, and coagulation function in patients with moderate to advanced lung cancer. It also improves patients' quality of survival with fewer adverse reactions and better disease control. These findings suggest that Gamma Knife SBRT is a promising treatment option and warrants further exploration and adoption in clinical practice.
Collapse
Affiliation(s)
- Chun-Guang Ling
- Department of Gamma Knife Treatment Center, Suzhou BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical UniversitySuzhou 215003, Jiangsu, China
| | - Jian-Feng Chen
- Department of General Surgery, Suzhou BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical UniversitySuzhou 215003, Jiangsu, China
| | - Xiao-Chen Wang
- Department of Thoracic and Cardiovascular Surgery, Suzhou BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical UniversitySuzhou 215003, Jiangsu, China
| |
Collapse
|
2
|
Virbel G, Mallereau CH, Lhermitte B, Feuvret L, Biau J, Clément L, Khoury C, Bernier V, Milhade N, Tanguy R, Colin P, Cébula H, Proust F, Bauchet L, Noël G. Radiotherapy for central neurocytoma: A multicentric retrospective study in France. Cancer Radiother 2024; 28:365-372. [PMID: 39095224 DOI: 10.1016/j.canrad.2024.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 03/14/2024] [Accepted: 03/16/2024] [Indexed: 08/04/2024]
Abstract
PURPOSE Neurocytomas represent 0.25 to 0.5% of primary brain tumours and are mainly found in young adults. These tumours have neuronal differentiation. The cornerstone treatment is neurosurgery. The efficacy of other therapies, including radiotherapy, is still unclear. The objective of this study was to evaluate the management of central neurocytomas and the role of radiotherapy. MATERIALS AND METHODS All adult patients (age 18 years or older) newly diagnosed with a histologically confirmed neurocytoma between 2006 and 2015 in France were included. RESULTS One hundred and sixteen patients were diagnosed with a central neurocytoma during the study period. All patients underwent surgical resection, and six received adjuvant radiotherapy. Eleven patients received radiotherapy due to progression. After a median follow-up of 68.7 months, local failure occurred in 29 patients. The 5-year local control rate was 73.4%. According to univariate analysis, marker of proliferation Ki67 index greater than 2% (hazard ratio [HR]: 1.48; confidence interval [CI]: 1.40-1.57; P=0.027) and subtotal resection (HR: 8.48; CI: 8.01-8.99; P<0.001) were associated with an increase in local failure. Gross total resection was associated with a higher risk of sequelae epilepsy (HR: 3.62; CI: 3.42-3.83; P<0.01) and memory disorders (HR: 1.35; CI: 1.07-1.20; P<0.01). Ten patients (8.6%) died during the follow-up. The 10-year overall survival rate was 89.0%. No prognostic factors for overall survival were found. CONCLUSION The analysis showed that patients who underwent subtotal surgical resection, particularly when the tumour had a Ki67 index greater than 2%, had an increased risk of local recurrence. These patients could benefit from adjuvant radiotherapy.
Collapse
Affiliation(s)
- Guillaume Virbel
- Department of Radiation Oncology, Unicancer, institut de cancérologie Strasbourg Europe (ICANS), 17, rue Albert-Calmette, BP 23025, 67033 Strasbourg, France
| | | | - Benoît Lhermitte
- Department of Anatomopathology, CHU de Hautepierre, 1, rue Molière, 67200 Strasbourg, France
| | - Loïc Feuvret
- Department of Radiation Oncology, CHU de Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - Julian Biau
- Department of Radiation Oncology, centre de lute contre le cancer Jean-Perrin, Unicancer, 58, rue Montalembert, 63011 Clermont-Ferrand, France
| | - Laurie Clément
- Department of Radiation Oncology, CHU Bretonneau, 2, boulevard Tonnellé, 37000 Tours, France
| | - Cédric Khoury
- Department of Radiation Oncology, centre de radiothérapie Saint-Louis Croix-Rouge française, 150, rue Nicolas-Appert, 83100 Toulon, France
| | - Valérie Bernier
- Department of Radiation Oncology, institut du cancer de Lorraine - Alexis-Vautrin, Unicancer, 6, avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France
| | - Nicolas Milhade
- Department of Radiation Oncology, institut Bergonié, Unicancer, 229, cour de l'Argonne, 33076 Bordeaux, France
| | - Ronan Tanguy
- Department of Radiation Oncology, centre Léon-Bérard, Unicancer, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France
| | - Philippe Colin
- Department of Radiation Oncology, polyclinique Courlancy, 38, rue de Courlancy, 51100 Reims, France
| | - Hélène Cébula
- Department of Neurosurgery, CHU de Hautepierre, 1, rue Molière, 67200 Strasbourg, France
| | - François Proust
- Department of Neurosurgery, CHU de Hautepierre, 1, rue Molière, 67200 Strasbourg, France
| | - Luc Bauchet
- Department of Neurosurgery, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34090 Montpellier, France; IGF, Inserm U1191, Montpellier, France
| | - Georges Noël
- Department of Radiation Oncology, Unicancer, institut de cancérologie Strasbourg Europe (ICANS), 17, rue Albert-Calmette, BP 23025, 67033 Strasbourg, France.
| |
Collapse
|
3
|
Maemura T, Katano A, Takami H, Nomura M, Takayanagi S, Yamashita H. Central Neurocytoma Treated Using Supratentorial Ventricle Radiotherapy: A Single-Institution Analysis of Five Cases in Adjuvant or Salvage Settings After Surgery. Cureus 2024; 16:e56132. [PMID: 38618419 PMCID: PMC11015110 DOI: 10.7759/cureus.56132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/13/2024] [Indexed: 04/16/2024] Open
Abstract
INTRODUCTION Central neurocytoma (CN) is an extremely rare tumor primarily located in the supratentorial ventricular system, categorized as a glioneuronal or neuronal tumor. METHODS This study presented a retrospective analysis of five CN patients who received adjuvant or salvage radiotherapy. Patients, aged 31-59 years, underwent radiation doses ranging from 60 Gy to 50.4 Gy over 27-30 fractions. RESULTS All patients achieved effective local tumor control without severe complications. The median follow-up period was 51.7 months, demonstrating 100% overall and progression-free survival rates. DISCUSSION Our study's clinical outcomes align with previous research, despite the limitation of a small sample size. Emphasizing the necessity for additional research, our findings added to the potential evidence of radiotherapy in managing CN. Larger, long-term studies were needed to confirm these promising results.
Collapse
Affiliation(s)
- Takeshi Maemura
- Department of Radiology, The University of Tokyo Hospital, Tokyo, JPN
| | - Atsuto Katano
- Department of Radiology, The University of Tokyo Hospital, Tokyo, JPN
| | - Hirokazu Takami
- Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, JPN
| | - Masashi Nomura
- Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, JPN
| | | | - Hideomi Yamashita
- Department of Radiology, The University of Tokyo Hospital, Tokyo, JPN
| |
Collapse
|
4
|
Spina A, Garbin E, Albano L, Bisoglio A, Boari N, Mortini P. Gamma Knife radiosurgery for central neurocytoma: a quantitative systematic review and metanalysis. Neurosurg Rev 2024; 47:64. [PMID: 38265530 DOI: 10.1007/s10143-024-02301-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 01/11/2024] [Accepted: 01/15/2024] [Indexed: 01/25/2024]
Abstract
Central neurocytomas (CN) are rare tumors within the central nervous system. Originating from the septum pellucidum and subependymal cells, they are typically found in the third and lateral ventricles. For this reason, they may lead to hydrocephalus and increased intracranial pressure. CNs are generally benign lesions that exhibit locally aggressive behavior and a high recurrence rate. Complete surgical resection is the preferred treatment; however, due to their anatomical location, this is often not feasible. Based on these findings, Gamma Knife radiosurgery (GKRS) has been introduced for managing both residual and recurrent tumors and as an initial therapy in selected cases. This study aimed to systematically review the available knowledge regarding GKRS for CN. A systematic investigation of the scientific literature was undertaken through an exhaustive search across prominent databases, including PubMed, Web of Science, and Google Scholar, by employing precise MeSH terms such as "Central neurocytoma," "Radiosurgery," "Gamma Knife," and "Stereotactic Radiosurgery." A comprehensive quantitative systematic review and meta-analysis were meticulously conducted, focusing on cases of CN treated with GKRS for a thorough evaluation of outcomes and efficacy. Seventeen articles, including 289 patients, met the inclusion criteria. Random effects meta-analysis estimates for disease control and local tumor control were 90% (95% CI 87-93%; I2 = 0%, p < 0.74) and 94% (95% CI 92-97%; I2 = 0%, p < 0.98), respectively. When considering only studies with at least 5 years of follow-up, progression-free survival was 89% (95% CI 85-94%; I2 = 0.03%, p < 0.74). The mean clinical control rate was 96%. This systematic review and meta-analysis confirmed the safety and efficacy of GKRS in managing CN.
Collapse
Affiliation(s)
- Alfio Spina
- Department of Neurosurgery and Gamma Knife Radiosurgery, I.R.C.C.S. San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy.
| | - Enrico Garbin
- Department of Neurosurgery and Gamma Knife Radiosurgery, I.R.C.C.S. San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
| | - Luigi Albano
- Department of Neurosurgery and Gamma Knife Radiosurgery, I.R.C.C.S. San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
| | - Andrea Bisoglio
- Department of Neurosurgery and Gamma Knife Radiosurgery, I.R.C.C.S. San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
| | - Nicola Boari
- Department of Neurosurgery and Gamma Knife Radiosurgery, I.R.C.C.S. San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
| | - Pietro Mortini
- Department of Neurosurgery and Gamma Knife Radiosurgery, I.R.C.C.S. San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy
| |
Collapse
|
5
|
Zhang Z, Yu J, Zhang C, Pang X, Wei Y, Lv Q, Chen H, Jin X, Zhan R. Clinical prognostic factors for central neurocytoma and subgroup analysis of different treatment measures: A SEER database-based retrospective analysis from 2003 to 2019. Front Oncol 2023; 12:1014506. [PMID: 36686752 PMCID: PMC9852998 DOI: 10.3389/fonc.2022.1014506] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Accepted: 12/19/2022] [Indexed: 01/07/2023] Open
Abstract
Purpose The study aimed to identify clinical prognostic factors affecting overall survival (OS) in patients with central neurocytoma (CN) and to determine independent prognostic factors in the subgroups of different treatment modalities using a retrospective analysis based on the SEER database from 2003 to 2019. Materials and methods Data regarding patients with CN, including basic clinical characteristics, treatment measures, and prognosis follow-up, were extracted from the SEER database. The prognostic variables for all patients were assessed using log-rank test as well as univariate and multivariate analyses based on the Cox proportional hazards model. The same statistical methods were used for analysis in different subgroups of gross total resection (GTR), subtotal resection (STR), no surgery, radiotherapy (RT), and no RT. Results In total, 413 patients were enrolled in this study. Tumor size, primary site surgery, and RT were independent prognostic factors in all patients with CN. In subgroup analyses, RT was not an independent prognostic factor in patients with GTR. However, sex and race were independent prognostic factors in patients with STR. Additionally, tumor size was an independent prognostic factor in patients who did not undergo surgery. Furthermore, sex and primary site were independent prognostic factors in patients who received RT. Size and primary site surgery were independent prognostic factors in patients without RT. Conclusion In our study, patients with small tumors or GTR or those who did not receive RT showed a better prognosis. GTR was the preferred treatment for CN. RT was not recommended for patients after GTR. Men and African American showed certain advantages after STR surgery. Tumors with a size of >4 cm were recommended for active treatment. In the RT subgroup, patients with tumors outside the ventricle or women had a poorer prognosis than those with tumors within the ventricle or men, respectively. These findings will help clinicians and patients understand the treatment and prognosis of CN visually and intuitively.
Collapse
Affiliation(s)
- Zibin Zhang
- Department of Neurosurgery, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Jianbo Yu
- Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Chao Zhang
- Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Xiaojun Pang
- Department of Neurosurgery, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Yuyu Wei
- Department of Neurosurgery, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Qingping Lv
- Department of Neurosurgery, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Huai Chen
- Department of Neurosurgery, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Xuhong Jin
- Department of Neurosurgery, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China,*Correspondence: Renya Zhan, ; Xuhong Jin,
| | - Renya Zhan
- Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,*Correspondence: Renya Zhan, ; Xuhong Jin,
| |
Collapse
|